Do you want to publish a course? Click here

A Comparative Study of The Effectiveness of Glibenclamide vs. Glibenclamide with Metformin in Controlling Diabetes Mellitus in Patients Enrolled in The National Program for Treatment of Diabetes Mellitus Type 2 in Syria

دراسة فعالية الغليبنكلاميد في ضبط سكر الدم و مقارنته مع مشاركة الغليبنكلاميد و الميتفورمين و ذلك لمراجع البرنامج الوطني لمعالجة الداء السكري من النمط الثاني في سورية

1111   0   2   0.0 ( 0 )
 Publication date 2013
  fields Pharmacy
and research's language is العربية
 Created by Shamra Editor




Ask ChatGPT about the research

This study aims to compare between two globally approved strategies to manage diabetes type II in Syria, by comparing their effectiveness in patients with diabetes type II who are treated in the national program of diabetes Clinics in Damascus and investigate their glucose control. The first strategy includes glibenclamide as a monotherapy and the second includes a combination of glibenclamide and metformin.


Artificial intelligence review:
Research summary
تتناول هذه الدراسة فعالية استراتيجيتين علاجيتين مختلفتين في إدارة مرض السكري من النمط الثاني. تم تقسيم المرضى إلى مجموعتين: الأولى تتلقى علاج الغليبنكلاميد فقط، والثانية تتلقى مزيجًا من الغليبنكلاميد والميتفورمين. تم متابعة المرضى لمدة ثلاثة أشهر، وتم تقييم الفعالية العلاجية بناءً على مستويات HbA1c. أظهرت النتائج أن العلاج المشترك كان أكثر فعالية في تحقيق مستويات HbA1c المستهدفة مقارنة بالعلاج الأحادي. كما أظهرت الدراسة أن الالتزام بأساليب العناية الذاتية مثل تناول الدواء، الحمية، وممارسة الرياضة كان له تأثير إيجابي على ضبط مستويات HbA1c.
Critical review
دراسة نقدية: تعتبر هذه الدراسة مهمة لأنها تقارن بين استراتيجيتين علاجيتين شائعتين في إدارة مرض السكري من النمط الثاني. ومع ذلك، يمكن أن تكون هناك بعض النقاط التي تحتاج إلى مزيد من التوضيح والتحليل. على سبيل المثال، لم يتم مناقشة الآثار الجانبية المحتملة للعلاج المشترك بشكل كافٍ، وهو ما يمكن أن يكون له تأثير كبير على جودة الحياة للمرضى. كما أن الدراسة لم تأخذ في الاعتبار العوامل الاجتماعية والاقتصادية التي قد تؤثر على التزام المرضى بالعلاج. بالإضافة إلى ذلك، يمكن أن تكون مدة الدراسة (ثلاثة أشهر) غير كافية لتقييم الفعالية الطويلة الأمد للعلاج.
Questions related to the research
  1. ما هي الفعالية العلاجية للعلاج المشترك مقارنة بالعلاج الأحادي؟

    أظهرت الدراسة أن العلاج المشترك كان أكثر فعالية في تحقيق مستويات HbA1c المستهدفة مقارنة بالعلاج الأحادي.

  2. ما هي مدة الدراسة وكيف تم تقييم الفعالية العلاجية؟

    تمت متابعة المرضى لمدة ثلاثة أشهر، وتم تقييم الفعالية العلاجية بناءً على مستويات HbA1c.

  3. ما هي العوامل التي أثرت على ضبط مستويات HbA1c؟

    الالتزام بأساليب العناية الذاتية مثل تناول الدواء، الحمية، وممارسة الرياضة كان له تأثير إيجابي على ضبط مستويات HbA1c.

  4. هل تم مناقشة الآثار الجانبية للعلاج المشترك؟

    لم يتم مناقشة الآثار الجانبية المحتملة للعلاج المشترك بشكل كافٍ في الدراسة.


References used
Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. Jan 2003;26 Suppl 1:S5-
Pittas A.pathophysiology of endocrinology,diabetes and metabolism.open course ware – tufts university.2005
Diagnosis and classification of diabetes mellitus. Diabetes Care. Jan 2010;33 Suppl 1:S67-24
rate research

Read More

Type 2 Diabetes mellitus T2DM has been suggested to be the most common metabolic disorder associated with magnesium deficiency which has many adverse outcomes. The aim of this study was to evaluate plasma Mg in 126 T2DM patients recruited from Dia betes Centre in Lattakia, compare them to 70 healthy individuals, and assess the correlation between plasma Mg and HbA1c as a glycemic control biomarker. Magnesium was measured using xylidyl blue colorimetric method. HbA1c was measured using ion-exchange resin separation. The SPSS 19.0 software was used for statistical analysis. Mean plasma Mg concentrations of the diabetics was significantly lower than controls (P=0.0001). Plasma magnesium was negatively correlated with HbA1c (r=-0.5, P=0.0002). Plasma magnesium was below the normal reference range (1.9-2.5 mg/dL) in 47.6% of diabetics and 28.6% of controls. In conclusion, it is important to monitor Mg levels in both T2DM patients and non-diabetics and take procedures to correct hypomagnesaemia states.
Blood glucose control reduces the microvascular and macrovascular complications in patients with diabetes mellitus type II. According to the American Diabetes Association, less than a half of those with diabetes achieve optimal control of blood gluc ose and target values of HbA1c. Life style modifications is one of the preferences of diabetes management because the potential relationship between diet and diabetic control. So nutrition therapy which given by dietitian and generally lifestyle modifications are considered mainly integrated to traditional medication for disease. The study included 104 patients with diabetes type II (HbA1c 8% ± 1.07, BMI 26.45 ± 2.69, fasting blood glucose 148.25 ± 33.76) given diabetes self-management education program and divided into two groups. The first group was treated with glibenclamide only and the second was treated with a combination of glibenclamide and metformin. After three months monitoring, 103 patients Completed the study. Therapeutic efficacy was evaluated considering HbA1c ≤ 6.5% as a target value. The necessary statistical study to analyze the data and evaluate the statistical significance of the results was made. The results indicate that the treatment supported with life style modifications was more effective than traditional therapy and patient education at blood glucose control in patients with diabetes mellitus type II and improve their health.
Background: Diabetes mellitus type2 (T2DM) and thyroid dysfunction (TD) are the two most common endocrine disorders in clinical practice. The unrecognized TD may adversely affect the metabolic control and add more risk to an already predisposing s cenario for cardiovascular diseases. The objective of this study was to investigate the prevalence of TD in patients with type2 diabetes mellitus. Objective: To determine the prevalence and patterns of thyroid dysfunction in patients with type2 diabetes mellitus. Material and methods: Study included total 362 subjects (204 type2 diabetic patients and 158 healthy non diabetic subjects). Agroup of type2 diabetic patients and control group were evaluated for thyroid dysfunction by testing TSH and FT4 when TSH was abnormal. The correlation of prevalence of thyroid disorder with gender distribution, age distribution, duration of diabetes, BMI, treatment, fasting plasma glucose (FPG), serum triglyceride and serum cholesterol was then done in diabetic patients. The observations and interpretations were recorded and results obtained were statistically analyzed. Results: The prevalence of thyroid dysfunction among type2 diabetic patients was found to be 13,2%. In the control group, the prevalence of thyroid dysfunction was 6,3%. There was a significant difference between diabetics and control subjects p= 0,031.The most frequently TD in type2 diabetic patients was subclinical hypothyroidism (8,3%). Thyroid dysfunction was significantly correlated with gender (women > man), age < 60 years, FPG > 130mg/dl, TG > 150mg/dl and insulin treatment in type2 diabetic patients. Conclusion: Screening of thyroid dysfunction shoud be done in all Type2 diabetic patients.
Many T2D use CAO as a laxative. We did not find sufficient research to explain CAO's potential effect on the levels of HbA1c in T2D patients. This study will study this effect. Rats (n=80) were divided into eight groups (n=10). Five groups (n=50) wer e injected with streptozotocin intravenously to induce T2D. One group was given CAO with empagliflozin, and the second was assigned CAO only daily. The third was assigned CAO every two days, with empagliflozin, which was given daily. A fourth was assigned CAO alone daily. Also, the fifth was given empagliflozin alone. In the healthy groups, one group was given CAO, and the other was given empagliflozin. Also, the last healthy group was not assigned any drug. CAO's result on HbA1c in healthy rats was noted to decrease when delivered alone for eight weeks. HbA1c of the diabetic groups showed no significant difference (P-value<0.05) when comparing the rats given CAO with empagliflozin, and the rats were given CAO only. There was also no noticeable effect among the groups of rats given CAO daily and every two days. This study explains that CAO does not lead to a significant difference in HbA1c levels in diabetic rats, even it did for healthy rats, and if given alone, CAO could affect HbA1c levels if given over a long period. Also, CAO has a noticeable impact on experimental rats that co-administered Empagliflozin on HbA1c levels, and that Empagliflozin effect is not significantly affected if taken with CAO.
comments
Fetching comments Fetching comments
Sign in to be able to follow your search criteria
mircosoft-partner

هل ترغب بارسال اشعارات عن اخر التحديثات في شمرا-اكاديميا